Immix Biopharma Inc (IMMX) Stock Price, Quote & News

Company Profile

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was in...

Industry: Biotechnology

Sector: Healthcare

Phone: 310 651 8041

Website: www.immixbio.com

Address:

11400 West Olympic Boulevard, Suite 200, Los Angeles, United States

Nwagn Nov. 14 at 8:07 PM

$IMMX we go higher next week

0 · Reply

Monica69 Nov. 14 at 7:04 PM

$IMMX LFG!! Still accumulating my Friends, GLTA. Good weekend!

1 · Reply

HedgeAlerts Nov. 14 at 6:52 PM

Hedge Alert Live - Protect Your Portfolio Contract: $IMMX $2.50 Put · NOV 21, 2025 Exp Entry Price: $0.10 - $0.50 Exit Price Target: $0.14 Profit Margin: +36% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Dingalingading Nov. 14 at 6:37 PM

$IMMX 4.40 LFG!

0 · Reply

BetterThanBuffett8 Nov. 14 at 6:04 PM

$IMMX It's really not that hard to imagine this becoming the new standard of care for AL Amyloidosis...not just for relaped refractory

1 · Reply

BetterThanBuffett8 Nov. 14 at 5:53 PM

$IMMX I thought it very telling when the guy doing the fireside chat at the Stifel Conference asked $IMMX if they were going to partner this and CFO Gabrielle Morris basically skirted the question and said "It's a big market "...

0 · Reply

Dingalingading Nov. 14 at 5:52 PM

$IMMX Lunch! RSI cooling. 👏

0 · Reply

Matt716 Nov. 14 at 4:54 PM

$IMMX I was right

1 · Reply

MoneyGroupLLC Nov. 14 at 4:53 PM

Enter: $IMMX Calls Strike Price: $5 Expiry Date: DEC 19 2025 Buy in Price: $0.15 - $0.30 Sell Price: $0.28 Profit : +88% (Turn every $1 into $1.88) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Bionco Nov. 14 at 4:52 PM

$IMMX wow! 😮

0 · Reply

Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch

Nov 6, 2025, 2:39 PM EST - 8 days ago

Immix Biopharma: I Am Surprised To Reaffirm A 'Buy'

Nov 3, 2025, 8:45 AM EST - 11 days ago

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

Oct 14, 2025, 8:45 AM EDT - 4 weeks ago

Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 6, 2025, 4:05 PM EDT - 5 weeks ago

Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting

Oct 1, 2025, 8:45 AM EDT - 6 weeks ago

Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference

$Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2$

Sep 18, 2025, 1:30 PM EDT - 2 months ago

Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2

Sep 11, 2025, 9:15 AM EDT - 2 months ago

Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors

Sep 8, 2025, 4:05 PM EDT - 2 months ago

Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang

Aug 25, 2025, 9:30 AM EDT - 2 months ago

Immix Biopharma to Present at the Stifel 2025 Healthcare Conference

Aug 6, 2025, 12:30 PM EDT - 3 months ago

Immix Biopharma Announces Other Serious Diseases Strategy

Jul 11, 2025, 9:36 AM EDT - 4 months ago

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion

$Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis$

Jul 7, 2025, 9:35 AM EDT - 4 months ago

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis

Jun 6, 2025, 9:39 AM EDT - 5 months ago

Immix Biopharma Attends FDA CEO Forum in Washington DC

$Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis$

Jun 3, 2025, 2:55 PM EDT - 5 months ago

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

$Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2$

May 23, 2025, 9:05 AM EDT - 6 months ago

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

$Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis$

May 22, 2025, 4:02 PM EDT - 6 months ago

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

$Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis$

May 21, 2025, 4:03 PM EDT - 6 months ago

Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis

Apr 23, 2025, 10:04 AM EDT - 7 months ago

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

$Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis$

Feb 10, 2025, 9:35 AM EST - 9 months ago

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

Jan 7, 2025, 9:34 AM EST - 11 months ago

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

$Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis$

Dec 19, 2024, 9:35 AM EST - 11 months ago

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis

$Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis$

Dec 16, 2024, 9:48 AM EST - 11 months ago

Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

$Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024$

Dec 10, 2024, 9:39 AM EST - 1 year ago

Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024

Dec 9, 2024, 9:33 AM EST - 1 year ago

Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media

$Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients$

Nov 25, 2024, 9:32 AM EST - 1 year ago

Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients

Oct 2, 2024, 9:32 AM EDT - 1 year ago

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2

Sep 19, 2024, 9:31 AM EDT - 1 year ago

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

$Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2$

Aug 28, 2024, 9:32 AM EDT - 1 year ago

Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

Jul 25, 2024, 9:36 PM EDT - 1 year ago

California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)

Jul 8, 2024, 9:31 AM EDT - 1 year ago

Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

Jun 17, 2024, 9:35 AM EDT - 1 year ago

Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum

$Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation$

May 10, 2024, 9:35 AM EDT - 1 year ago

Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation

Apr 29, 2024, 9:39 AM EDT - 1 year ago

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma

Apr 18, 2024, 9:32 AM EDT - 1 year ago

Immix Biopharma on Track to Dose NXC-201 Patients in United States

Apr 15, 2024, 9:36 AM EDT - 1 year ago

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Mar 20, 2024, 9:46 AM EDT - 1 year ago

Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

Mar 5, 2024, 9:35 AM EST - 1 year ago

Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative

Feb 21, 2024, 9:31 AM EST - 1 year ago

Immix Biopharma 12 Month Review Progress Update

Feb 8, 2024, 4:45 PM EST - 1 year ago

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

Feb 7, 2024, 9:37 AM EST - 1 year ago

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

Feb 5, 2024, 10:30 PM EST - 1 year ago

Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

Feb 5, 2024, 3:20 PM EST - 1 year ago

Immix Biopharma Announces Proposed Public Offering of Common Stock

Jan 24, 2024, 8:35 AM EST - 1 year ago

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

Dec 18, 2023, 9:39 AM EST - 2 years ago

Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board

$Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023$

Dec 11, 2023, 9:36 AM EST - 2 years ago

Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023

Dec 3, 2023, 2:02 AM EST - 2 years ago

Immix Biopharma: Seeking Catalysts To Propel Out Of Microcap Status

Nov 30, 2023, 9:46 AM EST - 2 years ago

Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit

$Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis$

Nov 22, 2023, 9:19 AM EST - 2 years ago

Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis

Nov 21, 2023, 9:46 AM EST - 2 years ago

Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing

Nwagn Nov. 14 at 8:07 PM

$IMMX we go higher next week

0 · Reply

Monica69 Nov. 14 at 7:04 PM

$IMMX LFG!! Still accumulating my Friends, GLTA. Good weekend!

1 · Reply

HedgeAlerts Nov. 14 at 6:52 PM

0 · Reply

Dingalingading Nov. 14 at 6:37 PM

$IMMX 4.40 LFG!

0 · Reply

BetterThanBuffett8 Nov. 14 at 6:04 PM

$IMMX It's really not that hard to imagine this becoming the new standard of care for AL Amyloidosis...not just for relaped refractory

1 · Reply

BetterThanBuffett8 Nov. 14 at 5:53 PM

0 · Reply

Dingalingading Nov. 14 at 5:52 PM

$IMMX Lunch! RSI cooling. 👏

0 · Reply

Matt716 Nov. 14 at 4:54 PM

$IMMX I was right

1 · Reply

MoneyGroupLLC Nov. 14 at 4:53 PM

0 · Reply

Bionco Nov. 14 at 4:52 PM

$IMMX wow! 😮

0 · Reply

keebs107 Nov. 14 at 4:36 PM

$IMMX Volume precedes price, turn it up and let it loose

0 · Reply

keebs107 Nov. 14 at 4:10 PM

$IMMX 4.20 will do the honors and light one up

0 · Reply

Dingalingading Nov. 14 at 4:10 PM

$IMMX 3.40,4.20---->5.15, 6.35,7.80

0 · Reply

DD_investments Nov. 14 at 4:07 PM

$IMMX took a little profit here but holding the rest. Could see another run to $8 like two years back, I think this gets bought out eventually

0 · Reply

ruck_my_life Nov. 14 at 3:56 PM

Last run above 4 was when I started accumulating $IMMX. I feel like this could be a breakout as people look for safer ports right now. Plus if I can get rich while saying "fuck cancer" that's about as good a day as you can ask for. .

0 · Reply

keebs107 Nov. 14 at 3:55 PM

$IMMX Lets see a shrek PP

1 · Reply

Nwagn Nov. 14 at 3:50 PM

$IMMX I meant don’t sell for cheap

0 · Reply

ImmxBeliever Nov. 14 at 3:44 PM

$IMMX More 13Fs this am

0 · Reply

ImmxBeliever Nov. 14 at 3:38 PM

$IMMX Let’s go !

0 · Reply

Dingalingading Nov. 14 at 3:22 PM

$IMMX ATH today!

0 · Reply

ruck_my_life Nov. 14 at 3:16 PM

$IMMX Literally the only thing I own that's green so folks if that's not a sell signal I don't know what is. .

1 · Reply

keebs107 Nov. 14 at 3:12 PM

$IMMX

0 · Reply

Market Cap	124.91M
Revenue (ttm)	0.00
Net Income (ttm)	-21.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	992,451
Avg Vol	527,390
Day's Range	N/A - N/A
Shares Out	33.58M
Stochastic %K	72%
Beta	0.33
Analysts	Sell
Price Target	$8.00